These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 17851558

  • 1. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
    Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T, Levis MJ, Neckers L, Trepel JB.
    Leukemia; 2007 Dec; 21(12):2476-84. PubMed ID: 17851558
    [Abstract] [Full Text] [Related]

  • 2. Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin.
    Kajiguchi T, Katsumi A, Tanizaki R, Kiyoi H, Naoe T.
    Eur J Haematol; 2012 Apr; 88(4):314-20. PubMed ID: 22126602
    [Abstract] [Full Text] [Related]

  • 3. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.
    Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
    [Abstract] [Full Text] [Related]

  • 4. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
    Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J.
    Blood; 2003 Jul 15; 102(2):646-51. PubMed ID: 12663439
    [Abstract] [Full Text] [Related]

  • 5. Leukemogenic potency of the novel FLT3-N676K mutant.
    Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.
    Ann Hematol; 2016 Apr 15; 95(5):783-91. PubMed ID: 26891877
    [Abstract] [Full Text] [Related]

  • 6. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
    Chougule RA, Kazi JU, Rönnstrand L.
    Oncotarget; 2016 Mar 01; 7(9):9964-74. PubMed ID: 26848862
    [Abstract] [Full Text] [Related]

  • 7. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
    Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel WE, Serve H.
    Cancer Res; 2005 Nov 01; 65(21):9643-50. PubMed ID: 16266983
    [Abstract] [Full Text] [Related]

  • 8. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
    Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, Fischer T, Berdel WE, Müller-Tidow C, Serve H.
    Blood; 2005 Jul 01; 106(1):265-73. PubMed ID: 15769897
    [Abstract] [Full Text] [Related]

  • 9. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
    Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, Carter GI, Grundy M, Shang S, Russell NH.
    Leukemia; 2006 Dec 01; 20(12):2130-6. PubMed ID: 17066094
    [Abstract] [Full Text] [Related]

  • 10. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
    Yi H, Zeng D, Shen Z, Liao J, Wang X, Liu Y, Zhang X, Kong P.
    Oncotarget; 2016 Jun 28; 7(26):40387-40397. PubMed ID: 27248172
    [Abstract] [Full Text] [Related]

  • 11. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H, Reinhardt J, Zaborski M, Drexler HG.
    Leukemia; 2003 Jan 28; 17(1):120-4. PubMed ID: 12529668
    [Abstract] [Full Text] [Related]

  • 12. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
    Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM.
    Leukemia; 2007 Mar 28; 21(3):439-45. PubMed ID: 17205056
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F, Steudel C, Oelschlägel U, Mohr B, Koch S, Ehninger G, Thiede C.
    Ann Hematol; 2010 Jul 28; 89(7):653-62. PubMed ID: 20119833
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
    Habif G, Grasset MF, Kieffer-Jaquinod S, Kuhn L, Mouchiroud G, Gobert-Gosse S.
    J Proteomics; 2013 Jan 14; 78():231-44. PubMed ID: 23017497
    [Abstract] [Full Text] [Related]

  • 16. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
    Schwäble J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, Steur C, Rehage M, Rudat A, Brandts C, Berdel WE, Müller-Tidow C, Serve H.
    Blood; 2005 Mar 01; 105(5):2107-14. PubMed ID: 15536149
    [Abstract] [Full Text] [Related]

  • 17. Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis.
    Jiang L, Zhao Y, Liu F, Huang Y, Zhang Y, Yuan B, Cheng J, Yan P, Ni J, Jiang Y, Wu Q, Jiang X.
    Cell Commun Signal; 2024 Aug 07; 22(1):391. PubMed ID: 39113090
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.